Anilinopyrimidine derivatives as JNK pathway inhibitors and...

Details Anilinopyrimidine derivatives as JNK pathway inhibitors and... Anilinopyrimidine derivatives as JNK pathway inhibitors and...

2006-10-31

2006-10-31

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253010, C514S256000

Reexamination Certificate

active

07129242

ABSTRACT:
Compounds having activity as inhibitors of the JNK pathway are disclosed. The compounds of this invention are anilinopyrimidine derivatives having the following structure:wherein R1through R6are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

REFERENCES:
patent: 4788195 (1988-11-01), Torley et al.
patent: 4876252 (1989-10-01), Torley et al.
patent: 4966622 (1990-10-01), Rempfler et al.
patent: 4973690 (1990-11-01), Rempfler et al.
patent: 5159078 (1992-10-01), Rempfler et al.
patent: 5166047 (1992-11-01), Hioki et al.
patent: 5262527 (1993-11-01), Gregory et al.
patent: 5489505 (1996-02-01), Kato et al.
patent: 5516775 (1996-05-01), Zimmerman et al.
patent: 5527914 (1996-06-01), Hioli et al.
patent: 5942384 (1999-08-01), Arai et al.
patent: 6114333 (2000-09-01), Davis et al.
patent: 6361760 (2002-03-01), Murata et al.
patent: 6552029 (2003-04-01), Davis
patent: 6693108 (2004-02-01), Green et al.
patent: WO 93/08167 (1993-04-01), None
patent: WO 98/18782 (1998-05-01), None
patent: WO 98/20003 (1998-05-01), None
patent: WO 99/01439 (1999-01-01), None
patent: WO 99/53927 (1999-10-01), None
patent: WO 99/63821 (1999-12-01), None
patent: WO 00/12486 (2000-03-01), None
patent: WO 00/15657 (2000-03-01), None
patent: WO 00/31067 (2000-06-01), None
patent: WO 00/33844 (2000-06-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/43373 (2000-07-01), None
patent: WO 00/56738 (2000-09-01), None
patent: WO 00/75118 (2000-12-01), None
patent: WO 00/78731 (2000-12-01), None
patent: WO 01/12621 (2001-02-01), None
patent: WO 01/14375 (2001-03-01), None
patent: WO 01/23382 (2001-04-01), None
patent: WO 01/27089 (2001-04-01), None
patent: WO 01/29009 (2001-04-01), None
patent: WO 01/91749 (2001-12-01), None
patent: WO 02/20512 (2002-03-01), None
patent: WO 02/46170 (2002-06-01), None
patent: WO 02/085396 (2002-10-01), None
Adam et al. “Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms.” Journal of Vasular Surgery, 1999, 30/4, pp. 641-650.
Yano et al. Differential activiation of cardiac c-Jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circular Research, 1998, 83 (7), pp. 752-760.
Li et al. Mol. Cell, Biol,. 16:5947-5954, 1996).
Aspenstrom et al., 1996, “Two GTPases, Cdc42 and Rac, bind directly to a protein implicated in the immunodeficiency disorder Wiskott-Aldrich syndrome”,Curr. Biol. 6:70-77.
Baeuerle and Baichwal, 1997, “NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules”,Advances in Immunology 65:111-137.
Beg et al., 1995, “Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-kappa B”, Nature 376(6536):167-70.
Bohrer et al., 1997, “Role of NFkappaB in the mortality of sepsis.”,J. Clin. Inv. 100:972-985.
Brand et al., 1997, “Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion”,J Clin Inv. 97:1715-1722.
Burke et al., 1999, “Peptides corresponding to the N and C termini of IkappaB-alpha, -beta, and -epilson as probes of two catalytic subunits of IkappaB kinase, IKK-1 amd IKK-2”,Journal of Biological Chemistry 274:36146-36152.
Chen et al., 1996, “Activation and inhibition of the AP-1 complex in human breast cancer cells”,Mol. Carcinogenesis15:215-226.
Cramer et al., 1999, “A firm hand on NFkappaB: structures of the IkappaBalpha-NFkappa B complex”,Structure 7:R1-R6.
Deacon et al., 1999, “MEK kinase 3 directly activates MKK6 and MKK7, specific activators of the p38 and c-Jun NH2-terminal kinases”,J. Biol. Chem. 274:16604-16610.
Delhase et al., 1999, “Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation”,Science 284:309-313.
Dong et al., 1998, “Defective T cell differentiation in the absence of Jnk1”,Science282:2092-2095.
Faris et al., 1996, “Regulation of interleukin-2 transcription by inducible stabile expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells”,J. Biol. Chem. 271:27366-27373.
Gosset et al., 1995, “Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients”,Int Arch Allergy Immunol. 106:69-77.
Gum et al., 1997, “Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades”,Oncogene14:1481-1493.
Han et al., 1999, “Jun N-terminal kinase in rheumatoid arthritis”,J. Pharm. Exp. Therap. 291:124-130.
Hibi et al., 1993, “Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain”, M.Genes Dev. 7:2135-2148.
Hu et al., 1999, “Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase”,Science 284:316-320.
Ishizuka et al., 1997, “Mast cell tumor necrosis factor alpha production is regulated by MEK kinases”,Proc. Nat. Acad. Sci. USA94:6358-6363.
Karin et al., 1997, “AP-1 function and regulation”,Curr Opin Cell Biol9:240-246.
Koch et al., 1995, “Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1”,Nature 376:517-519.
Lange-Carter et al., 1993, “A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.”,Science260:315-319.
Li et al., 1996, “The Ras-JNK pathway is involved in shear-induced gene expression”,Mol. Cell. Biol. 16:5947-5954.
Li et al., 1999, “IKK1-deficient mice exhibit abnormal development of skin and skeleton”,Genes&Development 13:1322-1328.
Li et al., 1999, “Severe liver degeneration in mice lacking the IkappaB kinase 2 gene.”,Science284:321-324.
Li et al., 1996, “Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+T cells”,Science271: 1272-1276.
Lin et al., 1995, “Identification of a dual specificity kinase that activates the Jun kinase and p38-Mpk2”,Science268:286-289.
Malinin et al., 1997, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1 ,Nature385:540-544.
Manning et al., “Transcription inhibitors in inflammation”,Exp. Opin. Invest. Drugs6: 555-567.
Mercurio et al., 1999, “IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex”,Mol Cell Biol. 19:1526-1538.
Mercurio et al., 1997, “IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation”,Science 278:860-866.
Milne et al., 1995, “p53 is phosphorylatedin vitroandin vivoby an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1”,J. Biol. Chem. 270:5511-5518.
Mohit et al., 1995, “p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system”,Neuron14:67-75.
Nishina et al., 1997, “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes”,J. Exp. Med. 186:941-953.
Okamoto et al., 1997, “Selective activation of the JNK/AP-1 pathway in Fas-mediated apoptosis of rheumatoid arthritis synoviocytes”,Arth&Rheum40: 919-926.
Panes et al., 1995, “Regional differences in constitutive and induced ICAM-1 expression in vivo,”Am J Physiol. 269:H1955-H1964.
Peet and Li, 1999, “kappaB kinases alpha and beta show a ran

Affiliated with

Also associated with

Rating

Anilinopyrimidine derivatives as JNK pathway inhibitors and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anilinopyrimidine derivatives as JNK pathway inhibitors and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anilinopyrimidine derivatives as JNK pathway inhibitors and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3667023